Company news
Madrigal Pharmaceuticals, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
February 11, 2025
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
January 12, 2025
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 2, 2025
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
November 5, 2024
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
October 30, 2024
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
October 29, 2024
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
October 20, 2024
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
October 17, 2024
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
October 1, 2024
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
September 30, 2024
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
September 29, 2024
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 25, 2024
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
August 6, 2024
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
August 1, 2024
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
July 23, 2024
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
June 5, 2024
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
May 28, 2024
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
May 6, 2024
Madrigal Statement on the Passing of Dr. Stephen Harrison
April 23, 2024
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
April 22, 2024
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 15, 2024
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
April 8, 2024
Madrigal Pharmaceuticals Announces Proposed Public Offering
March 17, 2024
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
March 17, 2024
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
March 13, 2024
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
March 4, 2024
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
February 27, 2024
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
February 7, 2024
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
January 28, 2024
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
January 3, 2024
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
November 20, 2023
Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health
November 9, 2023
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
November 9, 2023
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
November 5, 2023
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
September 27, 2023
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
September 12, 2023
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
September 10, 2023
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
August 7, 2023
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
July 16, 2023
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
June 29, 2023
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
June 21, 2023
Madrigal Pharmaceuticals Supports International NASH Day on June 8
June 5, 2023
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
May 31, 2023
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
May 10, 2023
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
May 8, 2023
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
April 17, 2023
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
February 22, 2023
Calls
The 5 newest of 12 calls. Every call is listed under its year.
- Madrigal Pharmaceuticals (NASDAQ:MDGL) Q3 2026 Earnings Call
Nov 3, 2026
Transcript - Madrigal Pharmaceuticals (NASDAQ:MDGL) Q2 2026 Earnings Call
Jul 30, 2026
Transcript - Madrigal Pharmaceuticals (NASDAQ:MDGL) Q1 2026 Earnings Call
May 6, 2026
Transcript - Madrigal Pharmaceuticals (NASDAQ:MDGL) Q4 2025 Earnings Call
Feb 19, 2026
Transcript - Madrigal Pharmaceuticals (NASDAQ:MDGL) Q3 2025 Earnings Call
Nov 4, 2025
Transcript
Decks
The 5 newest of 12 decks. Every deck is listed under its year.
- Q2 2026 Earnings Presentation
Earnings · 22 slides · Jul 30, 2026
- Q1 2026 Earnings Presentation
Earnings · 17 slides · May 6, 2026
- Q4 2025 Earnings Presentation
Earnings · 22 slides · Feb 19, 2026
- Q3 2025 Earnings Presentation
Earnings · 19 slides · Nov 4, 2025
- Q2 2025 Earnings Presentation
Earnings · 21 slides · Aug 5, 2025